Oxybutynin has been used for neurogenic bladder disorders and is known to have anti-cholinergic and antispasmodic properties. However, the anti-cholinergic and antispasmodic properties of 4-ethylamino-2-butynyl(2-cyclohexyl-2-phenyl)glycolate hydrochloride (N-desethyloxybutynin: DEOB), a metabolite of oxybutynin, have not been clarified. Therefore, in the present study, we studied these properties by using rat urinary bladder specimens in comparison with oxybutynin. Moreover, the effect of DEOB on rhythmic urinary bladder contraction was also evaluated using anesthetized rats. DEOB and oxybutynin concentration-dependently inhibited the carbachol-induced contraction, the pA 2 values being 7.19 and 7.11, respectively. DEOB and oxybutynin also concentration-dependently inhibited the 100 mM KCl-induced contraction, the ED 50 values being 12.1 and 10.4 mM, respectively. Intravenously administered DEOB and oxybutynin dose-dependently (0.03 -0.3 mg / kg) inhibited the amplitude of the rhythmic bladder contraction to similar degrees, but had no affect on the frequency. From the above results, it was determined that DEOB has anti-cholinergic and antispasmodic properties and that these activities were almost equal to those of oxybutynin. Therefore, DEOB may play an important role during oxybutynin therapy for neurogenic bladder disorder.
Introduction
In 1998, four types urinary incontinence were defined as urge, genuine stress, reflex, and overflow by the International Continence Society. Urge incontinence is frequently observed in elderly patients, especially in females, and the number of patients suffering from urinary incontinence has been increasing in the aging society.
To treat these patients, many drugs have been developed, such as anti-muscarinic drugs, oxybutynin and tolterodine, or papaverine like anti-spasmodic drugs, propiverine and flavoxate. Oxybutynin has been widely used in the clinic, but adverse effects, such as dry mouse, have been reported in the case of oral administration (1). Oki et al. (2) reported that oral administration of oxybutynin exhibited long term binding to muscarinic receptors in the salivary gland.
Recently, some pharmaceutical modification was performed to decrease the adverse effect of oxybutynin. Zobrist et al. (3) reported a low incidence of anti-cholinergic side effect by a novel matrix transdermal system. Lehtoranta et al. (4) reported the intravesical formulation of oxybutynin to decrease maximum concentration in serum after oral administration.
On the other hand, oxybutynin is metabolized to 4ethylamino-2-butynyl (2-cyclohexyl-2-phenyl) glycolate hydrochloride (N-desethyloxybutynin: DEOB) in the liver. However, there has been little clarification of anti-muscarinic and / or Ca 2+ -antagonistic properties of DEOB.
Thus, the present study was performed to clarify these properties by using rat urinary bladder specimens as compared with oxybutynin. Furthermore, the effect of DEOB on rhythmic urinary bladder contraction was also evaluated by using anesthetized normal rats.
Materials and Methods
The following animal studies were performed according to Guiding Principles for the Care and Use of Laboratory Animals Approved by The Japanese Pharmacological Society.
In vitro experiment
Smooth muscle tissue preparation and measurement of isometric force: Sprague-Dawley female rats weighing about 220 g (Charles River, Atsugi) were killed by a sharp blow to the head and exsanguination from the axillary artery. After the midline laparotomy, the urinary bladder was excised and removed. The urinary bladder was cut into two strips at the vertical axis (7 -15 mm length and 2 -3mm width). Isolated smooth muscle tissue was attached to a holder and the other side of the smooth muscle tissue was connected to the force transducer. Under a resting tension 0.5 g, the tissue was sustained in the organ bath containing modified Krebs solution (118 mM NaCl, 1.2 mM MgSO 4 , 1.2 mM CaCl 2 , 1.2 mM KH 2 PO 4 , 24.9 mM NaHCO 3 , and 11.1 mM glucose) saturated with 95% O 2 and 5% CO 2 mixture and kept at 37°C. In this experiment, the resting tension of 0.5 g was the optimal preload for force development in these preparations. After the equilibration for 60 -90 min, the smooth muscle contraction was recorded isometrically with an Automagnus testing system (AMT-100; Rikenkaihatsu, Tokyo).
Concentration-dependent relaxing effect of DEOB or oxybutynin against carbachol-induced contraction:
The tissue preparation was contracted by addition of carbachol at a concentration of 3´10 -5 M at least three times before the contractile response became stable. The procedure was repeated at 15-min intervals. After the contraction became stable, carbachol was cumulatively added to the organ bath, from 10 -7 to 10 -3 M, and concentration-dependent contractile curve was obtained. After washing out carbachol, oxybutynin or DEOB was added to the organ bath at an appropriate concentration. Five minutes after drug treatment, carbachol was added again cumulatively, and the concentration-dependent contractile curve was obtained at each concentration of oxybutynin or DEOB.
Concentration-dependent relaxing effect of DEOB or oxybutynin against KCl-induced contraction: The tissue preparation was contracted by the addition of KCl at a concentration of 100 mM at least three times before the contractile response became stable. The procedure was repeated at 15-min intervals. KCl was added again to the organ bath at a concentration of 100 mM. After stable tonic contraction was observed, oxybutynin or DEOB was added cumulatively to the organ bath, from 10 -7 to 10 -3 M, at appropriate intervals.
In vivo experiment
Rhythmic urinary bladder contraction: This experiment was performed according to the method of Dray and Metsch (5) with slight modification. Sprague-Dawley female rats weighing about 220 g (Charles River) were used in this experiment because a cannula could be easily inserted into the urinary bladder through the urethra without injuring the bladder. The rats were anesthetized with urethane (1.25 g / kg, s.c.). A polyethylene catheter (PE-50; Becton Dickinson Co., Franklin Lakes, NJ, USA) filled with saline was inserted into the bladder through the urethra and fixed to the skin around the urethra by silk thread. The urine was removed through the cannula by gently pressing the abdomen. The cannula was connected to a three-way stopcock. One outlet was connected to an amplifier (AP-601G; Nihon Kohden, Tokyo) by a pressure transducer (DX-360; Nihon Kohden). The intravesical pressure was recorded with a thermal pen-type recorder (WT-645G; Nihon Kohden). The other outlet was connected to a syringe filled with saline warmed at 37°C. At least 30 min after the operation, the bladder was filled through the injection tube with incremental 0.1-mL volumes of warmed saline at 37°C until spontaneous rhythmic urinary bladder contractions occurred reproducibly. Intravesical pressure was recorded. After the rhythmic urinary bladder contractions became stable, drugs were administered intravenously through the cannula inserted into the right jugular vein. The following parameters were evaluated: amplitude ( Fig. 1 ) and frequency of rhythmic urinary bladder contraction for 15 min. On the amplitude, the average of pretreatment value for a period of 15 min was taken as 100%, and the average of post-treatment values for the same period was calculated as percentage inhibition.
Chemicals
DEOB and oxybutynin was purchased from Orgamol S.A. (Evionnaz, Switzerland) and dissolved in DMSO (dimethylsulfoxide; Nacalai Tesque, Tokyo). Carbachol (carbamilcholine chloride) was purchased from Sigma (St. Louis, MO, USA). Other reagents were analytical grade and purchased from Wako Pure Chemical (Osaka) or Nacalai Tesque.
Statistical analyses
Results were expressed as the mean ± S.E.M. of used specimens or rats. In vitro study, pA 2 values were calculated from the Schild plot. IC 50 values were calculated from the concentration-dependent curve and confidence limit of 95% was calculated according to the Manual of Pharmacologic Calculations with Computer Programs (Second Edition). In vivo study, statistical analysis was performed by Dunnett's multiple comparison test and paired t-test, and results were regarded as significant when P<0.05.
Results

In vitro experiment
Concentration-dependent relaxing effect of DEOB or oxybutynin against carbachol-induced contraction: Carbachol induced a concentration-dependent contraction as shown in Fig. 2 . By the pre-treatment with DEOB, a concentration-dependent curve of carbachol shifted to the rightward direction in a concentrationdependent manner (Fig. 2 ) and the pA 2 value was calculated as 7.19. Oxybutynin also shifted the curve to the rightward direction in a concentration-dependent manner ( Fig. 3 ) and the pA 2 value was calculated as 7.11. The efficacy was almost the same between DEOB and oxybutynin.
Concentration-dependent relaxing effect of DEOB or oxybutynin against KCl-induced contraction: Against tonic contraction by KCl, DEOB relaxed in a concentration-dependent manner as shown in Fig. 4 and the IC 50 value was calculated as 12.1 m M (95% confidence limit: 5.6 -26.1 m M). Oxybutynin also relaxed in a concentration-depenedent manner as shown in Fig. 4 and the IC 50 value was calculated as 10.4 m M (3.4 -21.8 mM).
No significant difference was observed in antispasmodic effect between DEOB and oxybutynin.
In vivo experiment
Effect of DEOB on rhythmic urinary bladder contraction: In the control rats, the mean amplitude was 41.3 ± 8 and 39.0 ± 8.6 cmH 2 O before and after vehicle treatment, respectively; and the inhibitory percentage was 5.7 ± 0.6% (Table 1) . DEOB dose-dependently inhibited the amplitude of the rhythmic urinary bladder contrac- Fig. 1 . Representative cystometrogram of the rhythmic urinary bladder contraction in a rat. Amplitude is the maximum height of the cystometrogram. The rat was anesthetized and a polyethylene catheter was inserted into the bladder through the urethra. The cannula was connected to pressure transducer and the intravesical pressure was recorded as shown in this figure. tion, and significant differences were observed at doses of 0.1 and 0.3 mg / kg (P<0.05 and P<0.01). A representative inhibitory chart of DEOB at a dose of 0.3 mg / kg is shown in Fig. 5 . On the frequency of contractions, no significant difference was observed between before and after the treatment in the control group and even in the DEOB-treated groups ( Table 2) .
Effect of oxybutynin on rhythmic urinary bladder contraction: In the control rats, the mean amplitude was 38.3 ± 11.5 and 35.6 ± 11.9 cmH 2 O before and after vehicle treatment, respectively; and the inhibitory per-centage was 8.0 ± 2.4% (Table 3 ). Oxybutynin dosedependently inhibited the amplitude, and significant 5 . Representative cystometrogram of the rhythmic urinary bladder contraction in a rat administered DEOB. The rat was anesthetized and a polyethylene catheter was inserted into the bladder through the urethra. The cannula was connected to a pressure transducer and the intravesical pressure was recorded. DEOB at a dose of 0.3 mg /kg was administered intravenously through the cannula inserted into the right jugular vein.
differences were observed at doses of 0.1 and 0.3 mg / kg (P<0.05 and P<0.01). On the frequency of contractions, no significant difference was observed between before and after the treatment in the control group and even in the oxybutynin-treated groups ( Table 4 ).
Discussion
In the present study, it was found that DEOB had anticholinergic and antispasmodic properties and that these activities were almost equal to those of oxybutynin, respectively. Moreover, intravenously administered DEOB and oxybutynin dose-dependently inhibited the amplitude of the rhythmic bladder contraction to similar degrees, but did not affect the frequency of the contraction.
Oxybutynin is metabolized by oxidation to DEOB in the liver. Yaich et al. (6) reported that the CYP3A subfamily is involved in DEOB formation. Lukkai et al. (7) found that oxybutynin is predominantly metabolized to CYP3A4 and CYP3A5 in human liver microsomes. In the rats, oxybutynin is rapidly metabolized into two major primary oxidation products, DEOB and oxybutynin N-oxide (8) .
On the pharmacological properties of DEOB, Smith et al. (9) reported that de-ethylation of oxybutynin to DEOB does not appreciably alter its antimuscarinic or antispasmodic activity by using isolated strips of guinea pig bladder. Waldeck et al. (10) also found that oxybutynin and DEOB have a similar antimuscarinic effect in the human detrusor and the same binding characteristics in radioligand receptor binding study and that the pA 2 value of DEOB using acetylcholine was 7.8 in the human detrusor. In the present study, DEOB showed concentration-dependent antimuscarinic activity in the rat urinary bladder, and the pA 2 value using carbachol was 7.19. Although the experimental conditions were different between them, almost the same pA 2 values were obtained. In addition, DEOB showed a concentration-dependent antispasmodic effect on KCl-induced contraction and the IC 50 value was 10.4 mM.
Kaneko et al. (11) reported that the pA 2 value and IC 50 value of oxybutynin using acetylcholine and 100 mM KCl was 7.69 and 4.5 m M in the rat urinary bladder, respectively. In this study, these values of Values represent the mean ± S.E.M. of used rats. Values represent the mean ± S.E.M. of used rats. oxybutynin were 7.11 and 10.4 mM, respectively. In summary, it was found that DEOB have almost the same antimuscarinic and antispasmodic activity as oxybutynin in the rat urinary bladder specimens. Pharmacological characteristics of muscarinic receptors have been studied in many species (12 -17) . In the rat, muscarinic M 3 -receptor activation primarily causes direct contraction of the detrusor, whereas M 2 -receptor activation contracts the bladder indirectly by reversing sympathetically mediated relaxation (18) . Ikeda et al. (19) reported that oxybutynin showed antagonism against the M 3 -receptor of guinea pig urinary bladder smooth muscle. It would be very interesting to study the specificity of DEOB to muscarinic receptors.
In vivo study, Modiri et al. (20) reported that DEOB is less effective than oxybutynin on micturition pressure measured by cystometry in normal conscious rats. In this study, DEOB dose-dependently decreased the rhythmic urinary bladder pressure. However, the potency was almost equal to that of oxybutynin. The reason for this difference is not clear, although the experimental conditions were different from each other, the former is cystometry and the latter is rhythmic urinary bladder contraction.
Shimizu et al. reported the usefulness of oxybutynin in a rat bladder model with a unilateral electrolytic lesion of the basal forebrain (21) and in anesthetized rats with acetone induced cystitis (22) . Moreover, Sasaki et al. (23) reported that oxybutynin decreased the micturition pressure in both sham-operated and nervetransected rats without increasing the bladder capacity. Moreover, Guarneri et al. (24, 25) found the decrease of micturition pressure without effect on bladder capacity. These reports accorded with our findings that oxybutynin decreased the pressure of rhythmic urinary bladder contraction.
On the other hand, oxybutynin was reported to extend the micturition intervals in anesthetized rats with acetone-induced cystitis (22) and in conscious rats (26) . Shenot et al. (27) reported that oxybutynin increased bladder capacity in spinal-cord-injured rats. Moreover, Ishiura et al. (28) also found the increase in bladder capacity in cerebral infracted rats. In this study, DEOB and oxybutynin did not affect the frequency of rhythmic urinary bladder contraction. Sasaki et al. (23) reported no effect of oxybutynin on the bladder capacity in both sham-operated and nerve-transected rats. The reason for the difference in efficacy is not clear.
On the other efficacy of oxybutynin, Ishizuka et al. (29) recently found the role of central muscarinic receptors for micturition in normal conscious rats and reported that oxybutynin dose-dependently decreased the voiding pressure. De et al. (30) reported a local anesthetic effect on bladder afferent C fivers. Moreover, it was found that oxybutynin inhibited proliferation and suppressed gene expression in bladder smooth muscle (31) . However, the efficacy of DEOB has not been clarified on these points. Further investigations would be needed.
In summary, it became obvious that DEOB play an important role during oxybutynin therapy for neurogenic bladder disorder and that these activities were almost equal to those of oxybutynin in both in vitro and in vivo studies. In the human pharmacokinetic volunteer study, we found that the serum level of DEOB was higher than that of oxybutynin in case of oral administration (data not shown). Hughes et al. (32) reported that high levels of orally administered oxybutynin were matched by high DEOB metabolite levels in young, elderly and frail elderly volunteers. Moreover, Saitoh et al. (33) also reported that plasma levels of oxybutynin were almost equal to those of DEOB even in the instillation of intravesical oxybutynin in overactive bladder patients. In the present in vivo experiment, we used 0.3 mg / kg as the dose of DEOB administered intravenously. The concentration of DEOB in the blood stream is calculated as about 10 -5 M from the blood volume and molecular weight, being sufficiently effective against carbacholor KCl-induced contraction in the in vitro experiment. Therefore, we concluded that DEOB plays an important role in pharmacological profile of oxybutynin.
Part of this study was presented at the 75th Annual Meeting of The Japanese Pharmacological Society, 2002.
